Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ('Innate' or the 'Company') announced today that the abstract entitled 'A first-in-human study of CD123 NK Cell Engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia' was published on the ASCO 2023 Annual Meeting website.
The abstract concludes that SAR'579, in development by Sanofi, was well tolerated up to doses of 3 mg/kg QW with observed clinical benefit in patients with relapsed/refractory acute myeloid leukaemia (R/R AML).
'We are very pleased to see in this dose escalation Phase 1/2 update reported by Sanofi, the first clinical responses and good tolerability for SAR'579/IPH6101 targeting CD123 in relapsed/refractory acute myeloid leukaemia,' said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma. 'Although the data are preliminary, the clinical data from SAR'579 are encouraging, and we look forward to the full presentation of this trial at the 2023 ASCO Annual Meeting, as well as further updates as other assets of our ANKET platform enter the clinic.'
'The NK cell engager SAR'579, targeting CD123 is a remarkably designed investigational drug based on the ANKET platform and the result of a strong partnership between Sanofi and Innate scientists,' adds Valeria Fantin, Global Head of Oncology Research at Sanofi.
'It is exciting to see these early clinical results at the 2023 ASCO meeting,' said Peter. C. Adamson, MD, Global Head, Oncology Development at Sanofi. 'We look forward to the continued development of SAR'579 and are thankful to the investigators leading the clinical effort and the patients/families who have volunteered to participate in this trial.'
ASCO abstract presentation details: SAR'579 / IPH6101
Abstract: 7005
Abstract Title: A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.
Session Type/Title: Oral Abstract Session - Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant
Session Date and Time: 6/2/2023, 1:00 PM - 4:00 PM o Actual Presentation Time: 2:24 PM - 2:36 PM
About ANKET
ANKET (Antibody-based NK cell Engager Therapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer.
This versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer.
About the Innate-Sanofi agreement
The Company has a research collaboration and licensing agreement with Sanofi to apply Innate's proprietary technology to the development of innovative multi-specific antibody formats engaging NK cells through the activating receptors NKp46 and CD16 to kill tumor cells.
Under the terms of the 2016 research collaboration and licensing agreement, Sanofi is responsible for the development, manufacturing and commercialization of products resulting from the research collaboration, which includes IPH6101/SAR'579 (CD123 NK Cell Engager) and IPH6401/SAR'514 (BCMA NK Cell Engager). Innate Pharma will be eligible to up to EUR400m in development and commercial milestone payments as well as royalties on net sales.
Under the terms of a new license agreement entered in December 2022, which includes IPH62 (B7-H3 NK Cell Engager) and 2 options, Innate received EUR25m upfront payment and is eligible for up to EUR1.35bn total in preclinical, clinical, regulatory and commercial milestones plus royalties on potential net sales. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization.
Contact:
Tel: +33 (0)4 30 30 30 30
INNATE PHARMA 
